US 12,343,382 B2
Methods of using a GIP/GLP1 co-agonist for therapy
Charles T. Benson, Zionsville, IN (US); Axel Haupt, Zionsville, IN (US); Melissa Kay Thomas, Indianapolis, IN (US); and Shweta Urva, Indianapolis, IN (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Jul. 2, 2021, as Appl. No. 17/366,453.
Application 17/366,453 is a division of application No. 16/518,513, filed on Jul. 22, 2019, abandoned.
Claims priority of provisional application 62/740,619, filed on Oct. 3, 2018.
Claims priority of provisional application 62/730,565, filed on Sep. 13, 2018.
Claims priority of provisional application 62/702,061, filed on Jul. 23, 2018.
Prior Publication US 2021/0338781 A1, Nov. 4, 2021
Int. Cl. A61K 38/26 (2006.01)
CPC A61K 38/26 (2013.01) 51 Claims
 
1. A method of treating type 2 diabetes in a patient in need thereof, comprising: administering an escalation dose about once weekly for a minimum of at least about two weeks and thereafter administering a maintenance dose about once weekly for a minimum of at least about two weeks; wherein the escalation dose is selected from the group consisting of about 2.5 mg, about 7.5 mg and about 12.5 mg of tirzepatide, or a pharmaceutically acceptable salt thereof; and wherein the maintenance dose is selected from the group consisting of about 5.0 mg, about 10.0 mg and about 15.0 mg of tirzepatide, or a pharmaceutically acceptable salt thereof.